Evidence map›Paper›PMID 21078941›Full record

Trial reportAntimicrobial agents and chemotherapy2011

Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda.

Frederick N Baliraine, Samuel L Nsobya, Jane Achan, James K Tibenderana, Ambrose O Talisuna, Bryan Greenhouse, Philip J Rosenthal

Open access · bronzeAbstract readClinical TrialRandomized Controlled Trial
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Exploring the genetic progression of MDR1 inCurrent research in microbial sciences · 2024
    Article
  2. Analysis of Plasmodium falciparum NaBMC infectious diseases · 2019
    Article
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Frederick N BaliraineUniversity of California, San Francisco, CA 94143-0811, USA.
Samuel L Nsobya
Jane Achan
James K Tibenderana
Ambrose O Talisuna
Bryan Greenhouse
Philip J Rosenthal
University of California, San Francisco · USMakerere University · UGMalaria Consortium · UG

Funding

Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
Microbial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5M
Clinical &Molecular Studies of Drug Resistant MalariaU01AI052142 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2003 to 2008
$4.4M
TRAINING IN MALARIA RESEARCH IN UGANDAD43TW001506 · FIC · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2000 to 2004
$900k
Resistance of Malaria Parasites to Artemisinin-Based Combination TherapiesR56AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2008 to 2008
$618k
FIC NIH HHS D43 TW001506FIC NIH HHS TW01506NIAID NIH HHS 5T32AI060537NIAID NIH HHS AI075045NIAID NIH HHS AI52142NIAID NIH HHS R01 AI075045NIAID NIH HHS R56 AI075045NIAID NIH HHS T32 AI060537NIAID NIH HHS U01 AI052142
6 · The paper itself

Abstract

Quinine is a standard drug for treating severe malaria in Africa, and it is also increasingly used to treat uncomplicated disease. However, failures of quinine therapy are common, and it is unknown if failures in Africa are due to drug resistance. Recent studies have identified associations between in vitro quinine sensitivity and polymorphisms in genes encoding putative transporters, including well-described polymorphisms in pfcrt and pfmdr1 and varied numbers of DNNND or DDNHNDNHNND repeats in microsatellite 4760 (ms4760) of the predicted sodium-hydrogen exchanger, pfnhe1. To better characterize mediators of quinine response, we assessed associations between genetic polymorphisms, in vitro quinine sensitivity, and quinine treatment responses in Kampala, Uganda. Among 172 fresh clinical isolates tested in vitro, decreasing sensitivity to quinine was associated with accumulation of pfmdr1 mutations at codons 86, 184, and 1246. Nearly all parasites had pfcrt 76T, preventing analysis of associations with this mutation. pfnhe1 ms4760 was highly polymorphic. Parasites with 2 copies of either ms4760 repeat showed modest decreases in quinine sensitivity compared to those with 1 or ≥3 repeats, but the differences were not statistically significant. None of the above polymorphisms predicted treatment failure among 66 subjects treated with quinine for uncomplicated malaria. Our data suggest that quinine sensitivity is a complex trait and that known polymorphisms in pfcrt, pfmdr1, and pfnhe1, while associated with quinine sensitivity, are not robust markers for quinine resistance.

Indexed as

AntimalarialsPolymorphism, GeneticQuinineAmino Acid SequenceAnimalsATP-Binding Cassette, Sub-Family C ProteinsChildChild, PreschoolDrug ResistanceHumansInfantMalaria, FalciparumMembrane Transport ProteinsMicrosatellite RepeatsMolecular Sequence DataParasitic Sensitivity TestsAntimalarialsATP-Binding Cassette, Sub-Family C ProteinsMdr1 protein, Plasmodium falciparumMembrane Transport ProteinsPfCRT protein, Plasmodium falciparumProtozoan ProteinsQuinineSodium-Hydrogen Exchangers

Identifiers

PMID21078941
PMCPMC3028814
OpenAlexW2168864541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.